23/04/2026
Pfizer is gearing up to market a new Lyme vaccine globally. It will be sold in Australia which is interesting given the government still doesn’t “officially” recognise it.
After 12 years with chronic Lyme, I can’t stay quiet on this one. Here’s what most of us won’t see on the news. There are 20+ known strains of Borrelia, the bacteria behind Lyme. This vaccine targets only a fraction of them.
And most ticks don’t just carry Lyme. They carry Babesia. Bartonella. Anaplasma. Ehrlichia. Often all at once, and trust me, I know! A vaccine for one bug does nothing for the others.
Let’s also not forget the last Lyme vaccine, LYMErix was pulled from the market in 2002 after reports of autoimmune reactions. That history is relevant.
And the deeper question I can’t let go of: Why billions for a vaccine, and barely a cent for the chronically unwell who are already here, already suffering, already begging to be believed?
What the Lyme community truly needs is tick awareness, immune therapies, nervous system regulation, detox support, low inflammation food. A body given what it actually needs to heal.
You are a human being with the right to ask questions, read the fine print, and choose from a place of knowing.
Honestly, before you roll up your sleeve, please ask:
What strains does it actually cover?
What about co-infections?
What’s the long-term safety data?
And who benefits from a yes?
Your body. Your choice. Your research. Are you being helped, or being sold to? đź’š
Public service announcement: Pfizer is preparing to market its upcoming Lyme vaccine.
Major pharmaceutical launches typically involve large, coordinated campaigns across media, medicine, and policy. Pfizer is already hiring senior leadership focused on “market shaping” and driving vaccine uptake across healthcare systems.
As this vaccine moves closer to approval, it’s important for the public to understand how carefully these campaigns are designed, and how safety monitoring works once a product is released.
After vaccines are licensed and introduced, ongoing safety issues are primarily identified through passive adverse-event reporting systems and regulator-led pharmacovigilance.
This means that some risks may only become fully visible after widespread public use. In practice, post-market surveillance places part of the responsibility for detecting rare or delayed adverse effects on real-world patients, rather than identifying every possible issue before release.
Being informed about both the marketing process and the safety monitoring framework helps people make thoughtful, independent healthcare decisions.
See Lyme Advise’s informative post for more info on Pfizer’s marketing plans:
https://www.facebook.com/share/1CeKuKBDk7/?mibextid=wwXIfr
And Lymedisease.org’s excellent article on essential questions about the Lyme vaccine:
https://www.lymedisease.org/lyme-vax-essential-questions/